

Large-scale empirical identification of candidate comparators for pharmacoepidemiological studies

Justin Bohn¹
James P. Gilbert¹
Christopher Knoll¹
David M. Kern¹
Patrick B. Ryan¹

¹ Global Epidemiology Organization
Janssen Research and Development, LLC, Titusville, NJ, USA

Correspondence to:

Justin Bohn
1125 Trenton-Harbourton Road
Titusville, NJ, USA, 08560
jbohn2@its.jnj.com
+1 (857) 772-2015

Supplemental Material: Review of Published New User Cohort Design Studies

Description and Methodology

We searched the literature to identify high-quality observational studies employing new user (NU) designs and compared their comparator choices to our empirical estimates of similarity. We limited our search to papers published in the following journals in 2021 or later: *Science*, *Nature*, *The New England Journal of Medicine*, *JAMA*, *JAMA Internal Medicine*, *JAMA Surgery*, *JAMA Psychiatry*, *JAMA Cardiology*, *JAMA Pediatrics*, *JAMA Neurology*, *The Lancet*, *BMJ*, *Diabetes Care*, *Hypertension*, *Journal of the American College of Cardiology*, *Pharmacoepidemiology and drug safety*, *Drug safety*, *Annals of internal medicine*, *The Lancet. Digital health*, *The Lancet. Infectious diseases*, *The lancet. Diabetes endocrinology*, *The Lancet. Neurology*, *The Lancet. Oncology*, *The Lancet. Respiratory medicine*, *The lancet. Psychiatry*, and *The Lancet. Global health*. The full search parameters used are given below. Note that this literature review was performed in 2023 and, as such, the query below may yield additional results if submitted today.

Authors JB and PBR divided the set of returned publications and reviewed the full text of each to determine whether an NU design was in fact employed. For publications employing an NU design, all target-comparator pairs for which results were available were recorded verbatim, and the reviewer attempted to manually adjudicate each to an RxNorm ingredient or ATC level 4 class. In order to accommodate class-based cohorts found in the literature, we additionally generated similarity data for all ATC level 4 classes in the same manner as described for RxNorm ingredients in the main text. In some cases, target or comparator groups were defined as composites of individual ingredients and/or classes, in which case the reviewer created separate entries for each component and noted the mapping as

“partial”. Cohort similarity scores for all mapped target-comparator pairs were then obtained from the analytic pipeline described in the main text and are available as a separate Microsoft Excel workbook.

PubMed Query

("marketscan" OR "truven" OR "optum" OR "clinformatics" OR "iqvia" OR "pharmetrics" OR "administrative claims" OR "insurance claims" OR "healthcore" OR "aetna" OR "cigna" OR "humana" OR "sentinel")

AND

("cohort" AND ("comparator" OR "compared" OR "comparative" OR "propensity score" OR "versus"))

AND

("risk" OR "effect" OR "causal" OR "hazard" OR "exposure" OR "RR" OR "HR" OR "IRR" OR "rate ratio")

AND

("2021/01/01"[Date - Publication] : "3000"[Date - Publication])

AND

("Science"[Journal] OR "Nature"[Journal] OR "Nature Medicine"[Journal] OR "The New England journal of medicine"[Journal] OR "JAMA"[Journal] OR "JAMA internal medicine"[Journal] OR "JAMA Surgery"[Journal] OR "JAMA Psychiatry"[Journal] OR "JAMA Cardiology"[Journal] OR "JAMA Pediatrics"[Journal] OR "JAMA Neurology"[Journal] OR "Lancet"[Journal] OR "BMJ"[Journal] OR "Diabetes care"[Journal] OR "Hypertension"[Journal] OR "Journal of the American College of Cardiology"[Journal] OR "Pharmacoepidemiology and drug safety"[Journal] OR "Drug safety"[Journal] OR "Annals of internal medicine"[Journal] OR "The Lancet. Digital health"[Journal] OR "The Lancet. Infectious diseases"[Journal] OR "The lancet. Diabetes endocrinology"[Journal] OR "The Lancet. Neurology"[Journal] OR "The Lancet. Oncology"[Journal] OR "The Lancet. Respiratory medicine"[Journal] OR "The lancet. Psychiatry"[Journal] OR "The Lancet. Global health"[Journal])

AND

("Chemicals and Drugs Category"[Mesh]) NOT ("cross sectional") NOT ("Randomized Controlled Trial"[Publication Type] OR "Meta-Analysis"[Publication Type])

References Returned

1. Abrahami D, Tesfaye H, Yin H, Vine S, Hicks B, Yu OHY, et al. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. *Diabetes Care*. 2022;45:2907–17.
2. Adomi M, Kuno T, Komiyama J, Taniguchi Y, Abe T, Miyawaki A, et al. Association between pre-admission anticoagulation and in-hospital death, venous thromboembolism, and major bleeding among hospitalized COVID-19 patients in Japan. *Pharmacoepidemiol Drug Saf*. 2022;31:680–8.
3. Ajao A, Cosgrove A, Eworuke E, Mohamoud M, Zhang R, Shapira O, et al. A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants. *Pharmacoepidemiol Drug Saf*. 2022;31:1164–73.

4. Assimon MM, Pun PH, Wang LC-H, Al-Khatib SM, Brookhart MA, Weber DJ, et al. Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis. *JAMA Cardiol.* 2022;7:75–83.
5. Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, et al. Incidence of Acute Renal Failure in Patients Using Levetiracetam Versus Other Antiseizure Medications: A Voluntary Post-Authorization Safety Study. *Drug Saf.* 2022;45:781–90.
6. Brito JP, Deng Y, Ross JS, Choi NH, Graham DJ, Qiang Y, et al. Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults. *JAMA Intern Med.* 2022;182:418–25.
7. Chaudhary MFA, Hoffman EA, Guo J, Comellas AP, Newell JDJ, Nagpal P, et al. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study. *Lancet Digit Health.* 2023;5:e83–92.
8. Chen X, Affinati AH, Lee Y, Turcu AF, Henry NL, Schiopu E, et al. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. *Diabetes Care.* 2022;45:1170–6.
9. Chiuve SE, Kilpatrick RD, Hornstein MD, Petruski-Ivleva N, Wegrzyn LR, Dabrowski EC, et al. Chronic opioid use and complication risks in women with endometriosis: A cohort study in US administrative claims. *Pharmacoepidemiol Drug Saf.* 2021;30:787–96.
10. Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, et al. Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. *Drug Saf.* 2023;46:175–93.
11. Desai R, Park H, Brown JD, Mohandas R, Pepine CJ, Smith SM. Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta-Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension. *Hypertension.* 2022;79:2305–15.
12. Doege C, Luedde M, Kostev K. Association Between Angiotensin Receptor Blocker Therapy and Incidence of Epilepsy in Patients With Hypertension. *JAMA Neurol.* 2022;79:1296–302.
13. Dugani SB, Moorthy MV, Li C, Demler OV, Alsheikh-Ali AA, Ridker PM, et al. Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. *JAMA Cardiol.* 2021;6:437–47.
14. Elez E, Ros J, Fernández J, Villacampa G, Moreno-Cárdenas AB, Arenillas C, et al. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer. *Nat Med.* 2022;28:2162–70.
15. Evershed RP, Davey Smith G, Roffet-Salque M, Timpson A, Diekmann Y, Lyon MS, et al. Dairying, diseases and the evolution of lactase persistence in Europe. *Nature.* 2022;608:336–45.
16. Eworuke E, Hou L, Zhang R, Wong H-L, Waldron P, Anderson A, et al. Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin. *Drug Saf.* 2021;44:753–63.
17. Faquetti ML, la Torre AM-D, Burkard T, Obozinski G, Burden AM. Identification of polypharmacy

patterns in new-users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining. *Pharmacoepidemiol Drug Saf.* 2023;32:366–81.

18. Gaber CE, Kinlaw AC, Edwards JK, Lund JL, Stürmer T, Peacock Hinton S, et al. Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis : Two Nationwide Cohort Studies. *Ann Intern Med.* 2021;174:737–46.

19. Galbraith AA, Ross-Degnan D, Zhang F, Wu AC, Sinaiko A, Peltz A, et al. Controller Medication Use and Exacerbations for Children and Adults With Asthma in High-Deductible Health Plans. *JAMA Pediatr.* 2021;175:807–16.

20. GBD 2020, Release 1, Vaccine Coverage Collaborators. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. *Lancet.* 2021;398:503–21.

21. Goud R, Lufkin B, Duffy J, Whitaker B, Wong H-L, Liao J, et al. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries. *JAMA Intern Med.* 2021;181:1623–30.

22. Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, et al. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. *Drug Saf.* 2021;44:899–915.

23. Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, et al. Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. *Drug Saf.* 2023;46:157–74.

24. Kaplan S, Bertoia ML, Lass A, Wang FT, Evans A, Dhanda S, et al. Delayed pregnancy detection and return to fertility with extended levonorgestrel-containing oral contraceptives: A real world setting cohort study. *Pharmacoepidemiol Drug Saf.* 2023;32:78–83.

25. Kim WJ, Lee SJ, Lee E, Lee EY, Han K. Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study. *Diabetes Care.* 2022;45:134–41.

26. Kole TM, Vanden Berghe E, Kraft M, Vonk JM, Nawijn MC, Siddiqui S, et al. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study. *Lancet Respir Med.* 2023;11:55–64.

27. Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. *Nat Med.* 2023;29:127–34.

28. Lai FTT, Chan EWW, Huang L, Cheung CL, Chui CSL, Li X, et al. Prognosis of Myocarditis Developing After mRNA COVID-19 Vaccination Compared With Viral Myocarditis. *J Am Coll Cardiol.* 2022;80:2255–65.

29. Lau WCY, Torre CO, Man KKC, Stewart HM, Seager S, Van Zandt M, et al. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study. *Ann Intern Med.* 2022;175:1515–24.

30. Le Guen Y, Belloy ME, Grenier-Boley B, de Rojas I, Castillo-Morales A, Jansen I, et al. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. *JAMA Neurol.* 2022;79:652–63.
31. Lo Re V 3rd, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, et al. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients. *JAMA.* 2022;328:637–51.
32. Luo H, Lau WCY, Chai Y, Torre CO, Howard R, Liu KY, et al. Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic. *JAMA Psychiatry.* 2023;80:211–9.
33. Ly NF, Flach C, Lysen TS, Markov E, van Ballegooijen H, Rijnbeek P, et al. Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing Trends. *Drug Saf.* 2023;46:405–16.
34. Lyons JG, Suarez EA, Fazio-Eynullayeva E, Maro JC, Corey C, Li J, et al. Assessing medical product safety during pregnancy using parameterizable tools in the sentinel distributed database. *Pharmacoepidemiol Drug Saf.* 2023;32:158–215.
35. Lyu H, Zhao SS, Zhang L, Wei J, Li X, Li H, et al. Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study. *BMJ.* 2023;381:e073435.
36. Mack CD, DiFiori J, Tai CG, Shiue KY, Grad YH, Anderson DJ, et al. SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason. *JAMA Intern Med.* 2021;181:960–6.
37. Man KKC, Häge A, Banaschewski T, Inglis SK, Buitelaar J, Carucci S, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. *Lancet Psychiatry.* 2023;10:323–33.
38. Mortensen MB, Gaur S, Frimmer A, Bøtker HE, Sørensen HT, Kragholm KH, et al. Association of Age With the Diagnostic Value of Coronary Artery Calcium Score for Ruling Out Coronary Stenosis in Symptomatic Patients. *JAMA Cardiol.* 2022;7:36–44.
39. Newton ER, Akerman AW, Strassle PD, Kibbe MR. Association of Fluoroquinolone Use With Short-term Risk of Development of Aortic Aneurysm. *JAMA Surg.* 2021;156:264–72.
40. Noh Y, Jeong HE, Choi A, Choi E-Y, Pasternak B, Nordeng H, et al. Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children. *JAMA Pediatr.* 2023;177:267–77.
41. Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, et al. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. *JAMA Intern Med.* 2023;183:97–105.
42. Ouldali N, Varon E, Levy C, Angoulvant F, Georges S, Ploy M-C, et al. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study. *Lancet Infect Dis.* 2021;21:137–47.

43. Pal K, Sharma M, Mukadam NM, Petersen I. Initiation of antidepressant medication in people with type 2 diabetes living in the United Kingdom-A retrospective cohort study. *Pharmacoepidemiol Drug Saf.* 2022;31:892–900.
44. Pawar A, Gagne JJ, Gopalakrishnan C, Iyer G, Tesfaye H, Brill G, et al. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. *JAMA.* 2022;327:1051–60.
45. Prats-Urbe A, Sena AG, Lai LYH, Ahmed W-U-R, Alghoul H, Alser O, et al. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. *BMJ.* 2021;373:n1038.
46. Regan AK, Arriola CS, Couto P, Duca L, Loayza S, Nogareda F, et al. Severity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013-19: a surveillance-based cohort study. *Lancet Infect Dis.* 2023;23:222–32.
47. Sarayani A, Donahoo WT, Hampp C, Brown JD, Winterstein AG. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. *Ann Intern Med.* 2023;176:443–54.
48. Sarayani A, Hampp C, Brown JD, Donahoo WT, Winterstein AG. Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. *Drug Saf.* 2022;45:1517–27.
49. Simmering JE, Welsh MJ, Liu L, Narayanan NS, Pottgård A. Association of Glycolysis-Enhancing α -1 Blockers With Risk of Developing Parkinson Disease. *JAMA Neurol.* 2021;78:407–13.
50. Singer DE, Ziegler PD, Koehler JL, Sarkar S, Passman RS. Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke. *JAMA Cardiol.* 2021;6:1364–9.
51. Singh S, Cocoros NM, Haynes K, Nair VP, Harkins TP, Rochon PA, et al. Identifying prescribing cascades in Alzheimer’s disease and related dementias: The calcium channel blocker-diuretic prescribing cascade. *Pharmacoepidemiol Drug Saf.* 2021;30:1066–73.
52. Suarez EA, Nguyen M, Zhang D, Zhao Y, Stojanovic D, Munoz M, et al. Novel methods for pregnancy drug safety surveillance in the FDA Sentinel System. *Pharmacoepidemiol Drug Saf.* 2023;32:126–36.
53. Sun JW, Hernández-Díaz S, Haneuse S, Bourgeois FT, Vine SM, Olfson M, et al. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents. *JAMA Psychiatry.* 2021;78:91–100.
54. Tave A, Goehring E, Desai V, Wu C, Bohn RL, Tamayo SG, et al. Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. *Pharmacoepidemiol Drug Saf.* 2021;30:1353–9.
55. Toussi M, Shlaen M, Coste F, de Voogd H, Dimos V, Kaplan S. Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe. *Pharmacoepidemiol Drug Saf.* 2021;30:292–303.

56. Wang J, Gagne JJ, Kattinakere-Sreedhara S, Fischer MA, Bykov K. Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study. *BMJ*. 2022;379:e069931.
57. Wang Y-H, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children. *JAMA Pediatr*. 2021;175:394–403.
58. Wang Z, Chan AYL, Coghill D, Ip P, Lau WCY, Simonoff E, et al. Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age. *JAMA Intern Med*. 2021;181:1332–40.
59. Wen X, Lawal OD, Belviso N, Matson KL, Wang S, Quilliam BJ, et al. Association Between Prenatal Opioid Exposure and Neurodevelopmental Outcomes in Early Childhood: A Retrospective Cohort Study. *Drug Saf*. 2021;44:863–75.
60. Wong H-L, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. *Lancet*. 2022;399:2191–9.